Serialization Case Study: Aggregation And CMO Integration
Add bookmark
We respect your privacy, by clicking "Download Your Copy" you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here. Download PDF Attachment
As the pharmaceutical industry prepares itself for serialization, many questions arise in regards to best practices that will ensure product traceability throughout the supply chain and compliance on an international scale. In particular, manufacturers have expressed concern as to how their contract partners are preparing for and planning to hit the 2017 DSCSA deadline and what they can do to help them along. Aside from supply chain partner readiness, the decision to aggregate serialized product prior to 2023 is a top area of interest. We are leaning on the expert opinions of top pharmaceutical professionals for further clarification on these pain points.
Matt Sample, Senior Director, Secure Supply Chain at AmerisourceBergen, discusses aggregation challenges, possible solutions, and hitting DSCSA deadlines. He will elaborate on these ideas and more at this year’s Pharmaceutical Traceability Forum. Christopher Howell, Senior Director, Global Engineering & Technology at Patheon, Inc., shares his views on serialization and CMO integration, including some of the top challenges, possible explanations for increasing supply chain efficiency, and anticipated issues past 2017. Like Matt Sample and other distinguished speakers, he will also be presenting at the Pharmaceutical Traceability Forum.
Discover the key vulnerabilities to counterfeit activity in the supply chain and solutions to improve operational flexibility, build long-term resilience and cut supply chain costs. Download the Report.Pharma Logistics IQ Special Report: Combatting Counterfeit Activity in the Pharma industry
With insight from sector experts, learn how to identify weak points in your pharma supply chain and how you can secure them. Download the Pharma Logistics IQ report.“The first step is to acknowledge the problem, and then you can move on to risk management and analysis”
| Have Your Say Rate this feature and give us your feedback in the comments section below |
